Sunday 11 October 2026
Export all RLYB data to Excel Powerpack
Rallybio Corporation
RLYB Healthcare Biotechnology
In the quarter to June 2026, revenue was flat, EPS grew 535.2% and free cash flow grew 648.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
17.02
0.03
+0.18%
Follow RLYB
| Dec '17 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|
P/E ratio |
— | — | — | — | — | — | 0.00 | 0.00 |
P/S ratio |
— | — | — | — | — | — | 0.00 | 36.02 |
Altman Z-Score |
— | — | — | — | — | — | (3.97) | (3.12) |
P/FCF ratio |
— | — | — | — | — | — | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
— | — | — | — | — | — | (4.03) | 0.76 |
P/Operating CF |
— | — | — | — | — | — | (4.24) | (6.61) |
P/B ratio |
— | — | — | — | — | — | 0.68 | 0.53 |
Price to Tangible BV |
— | — | — | — | — | — | 0.68 | 0.53 |
EV/Sales |
— | — | — | — | — | — | 0.00 | (27.77) |
EV/EBITDA |
— | — | — | — | — | — | 0.38 | 0.71 |
EV/Operating CF |
— | — | — | — | — | — | 0.48 | 0.80 |
EV/FCF |
— | — | — | — | — | — | 0.48 | 0.80 |
Quick Ratio |
— | 5.11 | 24.00 | 26.76 | 15.73 | 11.87 | 10.50 | 12.96 |
Current Ratio |
— | 5.50 | 24.18 | 27.61 | 16.71 | 12.39 | 10.87 | 14.50 |
Net Debt/EBITDA |
— | 1.10 | 5.56 | 3.85 | 2.48 | 1.34 | 1.06 | 1.63 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 |
Operating CF/Net income |
— | 0.86 | 0.83 | 0.97 | 0.86 | 0.81 | 0.85 | 3.32 |
Capex/Depreciation |
— | 0.00 | (2.21) | (3.05) | 0.20 | 0.00 | 0.00 | 0.00 |
Interest Coverage |
— | (149.51) | (516.39) | (4,564.80) | (34.58) | — | — | — |
| — | 0.00% | (45.71%) | (30.17%) | (38.65%) | (54.13%) | (68.85%) | (15.01%) | |
| — | (162.57%) | (32.36%) | (29.02%) | (36.76%) | (50.37%) | (62.89%) | (13.77%) | |
ROIC |
— | 0.00% | 0.00% | (10,645.52%) | (13,135.45%) | 0.00% | 0.00% | (641.77%) |
Return on Tangible Assets |
— | (101.44%) | (19.49%) | (26.89%) | (39.41%) | (70.50%) | (93.62%) | (15.74%) |
Average Days of Receivables |
— | — | — | — | — | — | 0.00 | 0.00 |
Research and Development Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 6,526.26% | 2,284.03% |
Selling, General and Administrative Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 3,085.69% | 1,669.58% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | — | 0.00% | 0.00% | 0.00% | 0.00% | 1,256.76% | 619.35% |
Graham Net Nets |
— | — | — | — | — | — | 1.47 | 1.84 |
Graham Number |
— | — | — | — | — | — | 0.00 | 0.00 |
Earnings Yield |
— | — | — | — | — | — | (140.63%) | (28.80%) |
Free Cash Flow Yield |
— | — | — | — | — | — | (117.96%) | (96.55%) |
Revenue per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.12 | 0.15 |
Operating CF per Share |
— | (0.47) | (10.14) | (14.27) | (14.40) | (11.92) | (9.05) | (5.30) |
Capex per Share |
— | 0.00 | (0.06) | (0.10) | (0.01) | 0.00 | 0.00 | 0.00 |
Free Cash Flow per Share |
— | (0.47) | (10.20) | (14.38) | (14.42) | (11.92) | (9.05) | (5.30) |
Cash per Share |
— | 0.61 | 64.52 | 54.97 | 42.49 | 21.74 | 12.04 | 9.72 |
Shareholders Equity per Share |
— | 0.52 | 62.57 | 55.05 | 42.57 | 21.00 | 11.33 | 10.29 |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | 0.52 | 62.57 | 55.05 | 42.57 | 21.00 | 11.33 | 10.29 |
Free Cash Flow |
— | (15.03) | (22.18) | (45.87) | (57.34) | (60.28) | (49.28) | (29.81) |
Working Capital |
— | 17.11 | 135.42 | 174.32 | 168.75 | 105.53 | 61.60 | 57.03 |
Capital Expenditures |
— | (0.19) | (0.14) | (0.33) | (0.05) | (0.01) | — | — |
Net Current Asset Value |
— | 16.17 | 135.41 | 174.29 | 168.38 | 105.35 | 61.39 | 56.95 |
EV/EBIT |
— | — | — | — | — | — | 0.39 | 0.72 |
Capex to Sales |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Price to Operating Income |
— | — | — | — | — | — | 0.00 | 0.00 |
| Other line items | ||||||||
Depreciation/Fixed assets |
— | 0.13 | 0.22 | 0.21 | (0.70) | (11.95) | (12.88) | (20.91) |
Cash ROIC |
— | (41.37%) | (8.03%) | (13.07%) | (16.95%) | (27.89%) | (38.75%) | (26.46%) |
Accounts Receivable Turnover |
— | — | — | — | — | — | 0.00 | 0.00 |
Accounts Payable Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
— | 11,893.73 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Payables |
— | — | 1.22 | 1.09 | 0.86 | 1.05 | 0.63 | 0.20 |
Average Assets |
— | 10.80 | 81.73 | 162.02 | 181.31 | 148.03 | 91.86 | 65.18 |
Average Common Equity |
— | — | 57.86 | 155.80 | 172.46 | 137.75 | 83.92 | 59.81 |
Columns are period end dates